CuraSen Therapeutics to Present Late-Breaking, Phase 2a Exploratory Data with CuraAX (CST-3056) in Patients with Neurogenic Orthostatic Hypotension (nOH) at the 37th International Symposium on the Autonomic Nervous System

CuraSen Therapeutics said it will present late-breaking Phase 2a exploratory data for CuraAX (CST-3056) in patients with neurogenic orthostatic hypotension (nOH). The company will deliver an oral presentation at the 37th International Symposium on the Autonomic Nervous System, scheduled for Nov. 10–14, 2026, in San Diego, California. Anthony Ford, PhD, CuraSen’s president and chief scientific officer, will also give the Plenary Burnstock Lecture. CuraAX (CST-3056) is an oral, selective alpha1A-adrenoreceptor partial agonist in clinical development for nOH, a condition marked by sudden blood pressure drops upon standing or sitting that can lead to dizziness, fainting and cognitive impairment. The oral session is Thursday, Nov. 12, 11:00–11:15 a.m. PT; the virtual poster is #65.